Amgen Posts Weak Results, but Hails Osteoporosis Drug
119762
The biotechnology company said Thursday that its experimental osteoporosis drug proved superior to Fosamax from Merck in a clinical trial.
361386
Introgen Therapeutics Inc., a gene therapy company, on Thursday said its experimental breast cancer treatment showed promise in a mid-stage clinical trial, driving its shares up 24 percent.
15948
Genentech reported a 6 percent rise in fourth-quarter profit, but its stock slipped after news that its cancer drug, Avastin, failed to meet sales expectations.
652801
An experimental drug injected twice a year may prevent bone loss in postmenopausal women with low bone density, claims a new study funded by the drug&#39;s maker.
649663
LOS ANGELES/NEW YORK  - The U.S. Food and Drug   Administration said on Wednesday it had approved Amgen Inc.'s   drug Vectibix for use in colon cancer patients whose tumors   have spread despite chemotherapy treatment.
643383
If you're looking for evidence that diet and exercise can match the effectiveness of drugs in staving off osteoporosis in middle age, you're going to be disappointed.
750244
Amgen Inc. (AMGN.O: Quote, Profile, Research) , the world&#39;s biggest biotechnology company, on Wednesday said quarterly net profit fell on acquisition charges but adjusted earnings rose
220529
Amgen Inc. has added a warning to its anemia drug, Aranesp, for kidney dialysis and cancer patients after studies on similar drugs showed higher doses can cause blood clots and death, the company said a letter released on Friday.
766094
DUBLIN/NEW YORK  - Patients taking an experimental  multiple sclerosis drug developed by Biogen Idec Inc. BIIB.O  and Elan Corp. ELN.I experienced far fewer relapses in a  clinical trial, data that analysts say could give the drug a  dominant market position.
203886
The maker of the controversial diabetes pill Avandia pointed to early results of its own study Tuesday, saying they offered reassuring evidence the drug doesn't raise heart risks. However, outside experts called the results inconclusive at best and a sign of greater risk at worst.
454431
The drug company's experimental treatment for Alzheimer's  failed to prove effective in a big clinical trial. The stock  closed Tuesday at $45.85 on the New York Stock Exchange before  falling 10 percent in after-hours trading following release of  the trial results.
751523
A new addition to an already successful drug promises good results for investors.
151986
Drug makers Biogen Idec and Elan Corp. on Monday reported that its multiple sclerosis treatment reduced relapses by 66 percent in a late-stage trial.
683001
Patients taking an experimental multiple sclerosis drug developed by Biogen Idec Inc.  and Elan Corp.  experienced far fewer relapses in a clinical trial, data that analysts say could give the drug a dominant market position.
251805
NEW YORK  - The results of a new study suggest that Actonel (risedronate) provides greater fracture protection in the first year of therapy than does Fosamax (alendronate).
91923
NEW YORK/LOS ANGELES  - Amgen Inc  reported sharply lower third-quarter profit on Wednesday on plunging sales of its most important anemia drugs, amid new insurance-coverage restrictions and ongoing safety concerns, and on restructuring charges.
189115
LOS ANGELES/NEW YORK  - The U.S. Food and Drug   Administration said on Wednesday it had approved Amgen Inc's   drug Vectibix for the treatment of advanced colon cancer.